An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer

Cornelius F. Waller; Ihor Vynnychenko; Igor Bondarenko; Yaroslav Shparyk; Jeffrey P. Hodge; Anne Freeman; Brian Huber; Ronald Lieberman; Mark J. Shelton; Harish Dave

doi:10.1016/j.cllc.2014.10.001

An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer

Clinical Lung Cancer ◽

10.1016/j.cllc.2014.10.001 ◽

2015 ◽

Vol 16 (2) ◽

pp. 92-99 ◽

Cited By ~ 10

Author(s):

Cornelius F. Waller ◽

Ihor Vynnychenko ◽

Igor Bondarenko ◽

Yaroslav Shparyk ◽

Jeffrey P. Hodge ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽

Eribulin Mesylate ◽

Phase Ib ◽

Line Therapy

Download Full-text

Results from a phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.7035 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 7035-7035 ◽

Cited By ~ 7

Author(s):

T. Cufer ◽

E. Vrdoljak

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Randomized Study ◽

Small Cell ◽

Advanced Stage ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽

Line Therapy

Download Full-text

Open-label phase II study of S-1 as second-line therapy for patients with advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7580 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7580-7580 ◽

Cited By ~ 1

Author(s):

R. Govindan ◽

C. Zergebel ◽

K. Saito ◽

J. H. Schiller

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii Study ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽

Line Therapy ◽

Open Label Phase

Download Full-text

PD-070 SIGN: A Phase II, open-label, randomized study comparinggefitinib (IRESSA) with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

Lung Cancer ◽

10.1016/s0169-5002(05)80403-9 ◽

2005 ◽

Vol 49 ◽

pp. S87 ◽

Cited By ~ 1

Author(s):

T. Cufer ◽

E. Vrdoljak

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Randomized Study ◽

Small Cell ◽

Advanced Stage ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽

Line Therapy

Download Full-text

Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.02.009 ◽

2021 ◽

Author(s):

Fiona Blackhall ◽

Kevin Jao ◽

Laurent Greillier ◽

Byoung Chul Cho ◽

Konstantin Penkov ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Second Line ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Second Line Therapy ◽

Phase 3 ◽

Line Therapy

Download Full-text

Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTTION observational study

Current Medical Research and Opinion ◽

10.1185/03007995.2012.703133 ◽

2012 ◽

Vol 28 (8) ◽

pp. 1253-1262 ◽

Cited By ~ 7

Author(s):

Alain Vergnenegre ◽

Egbert F. Smit ◽

Elisabeth Toy ◽

Barbara Parente ◽

Stephan Schmitz ◽

...

Keyword(s):

Lung Cancer ◽

Clinical Practice ◽

Observational Study ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Second Line Therapy ◽

Treatment Pathways ◽

Line Therapy

Download Full-text

Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I–II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer

ESMO Open ◽

10.1136/esmoopen-2016-000132 ◽

2017 ◽

Vol 2 (2) ◽

pp. e000132 ◽

Cited By ~ 20

Author(s):

Floriana Morgillo ◽

Morena Fasano ◽

Carminia Maria Della Corte ◽

Ferdinando Carlo Sasso ◽

Federica Papaccio ◽

...

Keyword(s):

Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Advanced Lung Cancer ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽

Line Therapy ◽

Open Label Phase

Download Full-text

Second-line therapy of squamous non-small cell lung cancer: an evolving landscape

Expert Review of Respiratory Medicine ◽

10.1080/17476348.2017.1326822 ◽

2017 ◽

Vol 11 (6) ◽

pp. 469-479 ◽

Cited By ~ 7

Author(s):

Chiara Lazzari ◽

Niki Karachaliou ◽

Vanesa Gregorc ◽

Alessandra Bulotta ◽

Maria Gonzalez-Cao ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Second Line Therapy ◽

Line Therapy

Download Full-text

A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2019.01.008 ◽

2019 ◽

Vol 14 (5) ◽

pp. 903-913 ◽

Cited By ~ 38

Author(s):

Jean-Louis Pujol ◽

Laurent Greillier ◽

Clarisse Audigier-Valette ◽

Denis Moro-Sibilot ◽

Lionel Uwer ◽

...

Keyword(s):

Lung Cancer ◽

Cell Death ◽

Programmed Cell Death ◽

Small Cell Lung Cancer ◽

Phase Ii Study ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Second Line Therapy ◽

Line Therapy

Download Full-text

A retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced non-small-cell lung cancer (NSCLC)

Tumor Biology ◽

10.1007/s13277-016-5031-0 ◽

2016 ◽

Vol 37 (8) ◽

pp. 11479-11484 ◽

Cited By ~ 2

Author(s):

Rencui Quan ◽

Jiaxing Huang ◽

Nan Chen ◽

Wenfeng Fang ◽

Zhihuang Hu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Retrospective Analysis ◽

Cell Lung Cancer ◽

Small Cell ◽

Second Line ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Second Line Therapy ◽

Line Therapy

Download Full-text

Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer

Investigational New Drugs ◽

10.1007/s10637-005-0754-6 ◽

2005 ◽

Vol 23 (6) ◽

pp. 563-567 ◽

Cited By ~ 6

Author(s):

Afshin Dowlati ◽

Robert Chapman ◽

Shanmuga Subbiah ◽

Pingfu Fu ◽

Anne Ness ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Second Line Therapy ◽

Line Therapy ◽

Randomized Phase Ii

Download Full-text